580-P: Influence of Daily Step Counts on Glucose Outcomes in Adults with Type 1 Diabetes (T1D)
Authors: TURNER LAUREN , MARAK CHASE , CALHOUN PETER , GAL ROBIN L. , LI ZOEY , YOUNG GAVIN , PATTON SUSANA R. , CLEMENTS MARK A. , MARTIN CORBY K. , DOYLE FRANCIS J. , CASTLE JESSICA R. , GILLINGHAM MELANIE B. , RICKELS MICHAEL R. , BECK ROY , JACOBS PETER G. , RIDDELL MICHAEL 
Published: June 2023

Achieving 7-10K steps per day is recommended to maintain health; however, the influence of step count on time in range (70-180mg/dL: TIR), time above range (&gt;180mg/dL: TAR), and time below range (&lt;70mg/dL: TBR) in adults with T1D on different insulin delivery modalities (multiple daily injections [MDI], standard pump [SP], closed loop system [CLS]) is unclear. Using data from the Type 1 Diabetes Exercise Initiative, we examined the impact of failing to meet (&lt;7k), meeting (7k-10k) and exceeding (&gt;10k) step count goal on glycemic outcomes by insulin modality. Adults with T1D (37±14 yrs, 73% F, A1C 6.6±0.7%) wore a Verily Study Watch and CGM (Dexcom G6) for 4 weeks. Participants had at least two days where they failed to meet, met, and exceeded step count goal. For all users, mean TIR was 2% lower and TAR was 2% higher on days when participants failed to meet step count goal compared to meeting or exceeding step goal. TBR was 0.3% higher on days exceeding step count goal compared to failing to meet or meeting goal. Trends were similar across insulin delivery modalities, but variation differed, which affected significance levels. Meeting or exceeding 7-10K steps per day is associated with marginal improvements in TIR in adults with T1D.

Disclosure

L.Turner: None. F.J.Doyle: Other Relationship; Insulet Corporation, Roche Diabetes Care, Dexcom, Inc., Stock/Shareholder; Mode AGC. J.R.Castle: Advisory Panel; Novo Nordisk, Zealand Pharma A/S, Research Support; Dexcom, Inc., Stock/Shareholder; Pacific Diabetes Technologies. M.B.Gillingham: None. M.R.Rickels: Consultant; Sernova, Corp., Vertex Pharmaceuticals Incorporated, Zealand Pharma A/S, Research Support; Dompé. R.Beck: Consultant; Eli Lilly and Company, Novo Nordisk, Diasome, Insulet Corporation, Research Support; Tandem Diabetes Care, Inc., Beta Bionics, Inc., Dexcom, Inc., Bigfoot Biomedical, Inc., Medtronic, Ascensia Diabetes Care, Roche Diabetes Care, Eli Lilly and Company, Novo Nordisk. P.G.Jacobs: Board Member; Pacific Diabetes Technologies, Other Relationship; Pacific Diabetes Technologies, Research Support; Dexcom, Inc. M.Riddell: Advisory Panel; Zealand Pharma A/S, Zucara Therapeutics, Indigo Diabetes, Consultant; Lilly Diabetes, Eli Lilly and Company, Jaeb Center for Health Research, Speaker's Bureau; Dexcom, Inc., Novo Nordisk, Sanofi, Stock/Shareholder; Supersapiens, Zucara Therapeutics. T1dexi study group: n/a. C.Marak: None. P.Calhoun: None. R.L.Gal: None. Z.Li: None. G.Young: None. S.R.Patton: None. M.A.Clements: Consultant; Glooko, Inc., Research Support; Dexcom, Inc., Abbott Diabetes. C.K.Martin: Board Member; EHE Health, Wondr Health, Other Relationship; ABGIL, Research Support; Pack Health, Evidation Health, Lilly, WW International, Inc.

Funding

The Leona M. and Harry B. Helmsley Charitable Trust; Verily Life Sciences; Dexcom, Inc.